miRNA-SNP analysis as potential biomarkers of adverse reactions by molecular-targeted agents
| Project/Area Number |
15K14999
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
Katayama Koki
Nakashima Shimon
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | マイクロRNA / SNP / 遺伝子多型 / バイオマーカー / 個人差 |
|---|
| Outline of Final Research Achievements |
We analyzed the miRNA-SNPs in Japanese subjects targeting 1,900 pre-miRNAs to investigate whether there are ethnic differences in their allele frequencies, and to identify biomarkers, which are useful to predict adverse reactions of anti-cancer drugs or incidence of cancers. Approximately 150 miRNA-SNPs were found in a person on average for healthy subjects and cancer patients. We found several miRNA-SNPs whose frequencies were significantly different with in global populations, suggesting ethnic differences. We identified miRNA-SNPs whose frequencies were different between healthy subjects and non-small cell lung cancer, colorectal cancer, or adult T-cell / leukemia patients. These miRNA-SNPs can be biomarkers of incidence of each cancer.
|
Report
(4 results)
Research Products
(11 results)
